Gala review

Gala is an app and telehealth platform connecting patients with separate medical practices and pharmacy fulfillment. Its menu spans compounded GLP-1s, menopause hormone care, NAD+ and sermorelin. The terms identify AI Coaching as the platform operator and describe medical decisions as belonging to the participating professionals. A shared account can make service comparisons convenient, but the menu does not establish that several treatments should be combined. Ask which medical group, clinician and pharmacy would handle your particular prescription. The company advertises service in all fifty states; the actual treatment and prescribing authorization still need confirmation for your location.

The current compounded GLP-1 page labels its low headline as a yearly subscription equivalent. That is different from a standing month-to-month quote. The previously recorded monthly checkout no longer establishes a current offer, so those older figures are withheld. Before choosing a long plan, request the full payment, the commitment period, supply per shipment, later renewal amount and cancellation consequences. The company advertises no membership fee and a flat GLP-1 price across doses. Confirm those inclusions for the selected agreement rather than assuming every medication, formulation, required lab or brand-access option has the same bundle.

The NAD+ and sermorelin pages describe at-home injections after written clinical review, with no video appointment required in that advertised pathway. They show a monthly starting label next to a twenty-eight-day supply and a separate twelve-month equivalent. A supply duration alone does not establish the exact dates on which your card is charged. Obtain that schedule before treating the headline as either a calendar-month subscription or fixed four-week billing. The pages include provider review and shipping, with an initial month and two refills on file, followed by a quarterly questionnaire. Continued supply remains subject to clinical eligibility rather than an unconditional entitlement.

The app describes dose logging, reminders and care-team communication. Those features can help organize an existing prescription, but they are not evidence that a medicine is appropriate or that a particular outcome is likely. NAD+ cellular biology does not prove improved energy from the commercial injection, and stimulating growth-hormone signaling is not proof of better sleep, recovery or muscle. The sermorelin page promotes a scheduled break to prevent tolerance; that should be discussed as the provider’s protocol rather than an established requirement for all preparations. Do not transfer a marketed timing claim or combination suggestion into your own treatment plan without the clinician explaining its evidence and limitations.

Read the refund policy before paying. It says the first charge occurs after intake and promises a full refund for initial medical disqualification. Its later refund section discusses the remaining service after medical disqualification, limits approved refunds to the most recent billing cycle, and also uses conditional wording for later ineligibility. Those passages do not justify promising the return of every past payment. For nonmedical cancellation, it generally rules out refunds. Requests must arrive at least 72 hours before the billing date; otherwise another cycle can be charged before the cancellation takes effect. Keep written confirmation, particularly for a prepaid or yearly commitment.

Damaged or incorrect medication follows a separate reporting and replacement process. Contact the service promptly and preserve evidence of damage; the policy describes possible pharmacy replacement rather than an automatic cash refund. Terms state that third-party pharmacies dispense prescriptions but do not identify the assignment for every patient. Confirm the facility and its label instructions, including storage and beyond-use limits, before relying on a general licensed-pharmacy statement. Menopause treatment also needs its own price and monitoring discussion. A broad no-lab or no-video slogan should not override an individualized request for testing or a consultation, and the platform’s advertised availability is not an external credential verification.